Busulfan and Veno-occlusive Disease of the Liver
Authors: Gilles Vassal
Journal: Annals of Internal Medicine (1990)

Letters and Corrections1 June 1990Busulfan and Veno-occlusive Disease of the LiverGilles Vassal, MD, Olivier Hartmann, MD, Ellen Benhamou, MDGilles Vassal, MDSearch for more papers by this author, Olivier Hartmann, MDSearch for more papers by this author, Ellen Benhamou, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-112-11-881_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor:High-dose busulfan in combination therapy is well known to be responsible for veno-occlusive disease of the liver in about 20% of adult patients undergoing bone marrow transplantation (1, 2). However, the incidence of this disease is lower (0% to 5%) in children (3). In our institution, from September 1979 to December 1990, 403 courses of high-dose chemotherapy were administered before bone marrow transplantation in children with solid tumors: 125 courses included high-dose busulfan. Two total busulfan doses were used: 16 mg/kg body weight in 64 courses and 600 mg/m2body surface area in 61 courses. The dose...References1. McDonaldSharmaMatthewsSchulmanThomas GPDHE. The clinical course of 53 patients with veno-occlusive disease of the liver after bone marrow transplantation. Transplantation. 1985;39:603-8. CrossrefMedlineGoogle Scholar2. GrochowJonesBrundrett LRR. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25:55-61. CrossrefMedlineGoogle Scholar3. BrugieresHartmannBenhamou LOE. Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: incidence, clinical course and outcome. Bone Marrow Transplant. 1988;3:53-8. MedlineGoogle Scholar4. HassanObergEhrsson MGH. Pharmacokinetics and metabolic studies of high-dose busulfan in adults. Eur J Clin Pharmacol. 1989;36:525-30. CrossrefMedlineGoogle Scholar5. VassalGouyetteHartmannPicoLemerle GAOJJ. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol. 1989;24:386-90. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Gilles Vassal, MD; Olivier Hartmann, MD; Ellen Benhamou, MDAffiliations: Institut Gustave Roussy Ville juif 94805, France PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byImpact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantationBusulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trialGas chromatographic–mass spectrometric quantitation of busulfan in human plasma for therapeutic drug monitoring: A new on-line derivatization procedure for the conversion of busulfan to 1,4-diiodobutaneEvaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipientsBOrder of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCTThe Gastrointestinal Complications of Oncologic TherapyGastrointestinal complications of oncologic therapyThe effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse modelSafe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimenHepatotoxicity of ChemotherapyVascular Toxicity of Antineoplastic AgentsEffect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in micePharmacokinetics of high-dose chemotherapy6-Thioguanine in the Treatment of Psoriasis: A Case Report and Literature ReviewHepatotoxicity of chemotherapyHepatotoxicity of ChemotherapyThe role of busulfan in bone marrow transplantationPediatric oncology and AIDS: therapeutic lessons of relevance to generic drug useThe Syndrome of Veno-occlusive Disease After Blood or Marrow TransplantationWill high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma?HEPATOTOXICITY OF CHEMOTHERAPEUTIC AND ONCOLOGIC AGENTSA gas-chromatographic assay method for busulfan with sensitivity for test dose therapeutic monitoringBusulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantationPharmacokinetic variability in the adolescent: Implications of body size and organ function for dosage regimen designBusulfan6-Thioguanine therapy for psoriasis causing toxic hepatic venoocclusive diseaseHepatic veno-occlusive disease after bone marrow transplantGas-chromatographic analysis of busulfan for therapeutic drug monitoringCytostatics and immunosuppressive drugs 1 June 1990Volume 112, Issue 11Page: 881-881KeywordsBody surface areaBody weightBone marrow transplantationChildrenHigh-dose chemotherapyLiver diseasesLiver transplantation ePublished: 1 December 2008 Issue Published: 1 June 1990 PDF downloadLoading ...